Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Adenoviral-mediated Interferon-beta · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Dose level 4 | EXPERIMENTAL | - |
| Dose level 5 | EXPERIMENTAL | - |
| Dose Level 1 | EXPERIMENTAL | on Days 1 and 15 |
| Dose Level 2 | EXPERIMENTAL | On Days 1 and 15 |
| Dose Level 3 | EXPERIMENTAL | On Days 1 and 15 |
| Name | Type | Description |
|---|---|---|
| Adenoviral-mediated Interferon-beta | BIOLOGICAL | BG00001 at doses 1.5 x 10e12 and 3 x 10e12 viral particles Days 1 and 8 |
| SCH 721015 | BIOLOGICAL | Comparison of different doses and frequency of investigational agent |
Inclusion Criteria: * must have malignant pleural effusion from mesothelioma or metastatic from primary lung, breast, gastrointestinal, genitourinary, melanoma, or sarcoma * must have evaluable disease * must have ECOG performance status of 2 * must have pleural space involved with tumor accessible...
Adenoviral-mediated Interferon-beta is an investigational gene therapy being studied for the treatment of pleural mesothelioma and metastatic pleural effusions. It is administered via gene therapy to deliver interferon-beta to the affected area. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Adenoviral-mediated Interferon-beta is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The company is conducting clinical research on this investigational therapy for pleural mesothelioma and metastatic pleural effusions.
Adenoviral-mediated Interferon-beta is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The Phase 1 trial has been completed, and the drug remains in early-stage clinical research.
Adenoviral-mediated Interferon-beta has one completed clinical trial registered under NCT00299962, titled 'Gene Therapy for Pleural Malignancies.' This Phase 1 study enrolled 17 participants in the United States with pleural mesothelioma or metastatic pleural effusions. The trial was controlled but not randomized or double-blinded.
Adenoviral-mediated Interferon-beta works by using an adenoviral vector to deliver the gene for interferon-beta directly into the pleural space. This approach aims to produce interferon-beta locally, which may help treat pleural malignancies. The drug is designed to target cancer cells in the pleural cavity.